Saltar al contenido
Merck
  • Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.

Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.

Lancet (London, England) (2013-07-23)
Sophie A Jamal, Ben Vandermeer, Paolo Raggi, David C Mendelssohn, Trish Chatterley, Marlene Dorgan, Charmaine E Lok, David Fitchett, Ross T Tsuyuki
RESUMEN

Phosphate binders (calcium-based and calcium-free) are recommended to lower serum phosphate and prevent hyperphosphataemia in patients with chronic kidney disease, but their effects on mortality and cardiovascular outcomes are unknown. We aimed to update our meta-analysis on the effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease. We did a systematic review of articles published in any language after Aug 1, 2008, up until Oct 22, 2012, by searching Medline, Embase, International Pharmaceutical Abstracts, Cochrane Central Register of Controlled Trials, and Cumulative Index to Nursing and Allied Health Literature. We included all randomised and non-randomised trials that compared outcomes between patients with chronic kidney disease taking calcium-based phosphate binders with those taking non-calcium-based binders. Eligible studies, determined by consensus with predefined criteria, were reviewed, and data were extracted onto a standard form. We combined data from randomised trials to assess the primary outcome of all-cause mortality using the DerSimonian and Laird random effects model. Our search identified 847 reports, of which eight new studies (five randomised trials) met our inclusion criteria and were added to the ten (nine randomised trials) included in our previous meta-analysis. Analysis of the 11 randomised trials (4622 patients) that reported an outcome of mortality showed that patients assigned to non-calcium-based binders had a 22% reduction in all-cause mortality compared with those assigned to calcium-based phosphate binders (risk ratio 0·78, 95% CI 0·61-0·98). Non-calcium-based phosphate binders are associated with a decreased risk of all-cause mortality compared with calcium-based phosphate binders in patients with chronic kidney disease. Further studies are needed to identify causes of mortality and to assess whether mortality differs by type of non-calcium-based phosphate binder. None.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Carbonato de calcio, ACS reagent, ≥99.0%, powder
Sigma-Aldrich
Carbonato de calcio, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E170, precipitated, 98.5-100.5% (based on anhydrous substance)
Sigma-Aldrich
Carbonato de calcio, powder, ≤50 μm particle size, 98%
Sigma-Aldrich
Carbonato de calcio, ReagentPlus®
Sigma-Aldrich
Carbonato de calcio, ACS reagent, chelometric standard, 99.95-100.05% dry basis
Sigma-Aldrich
Carbonato de calcio, 99.999% trace metals basis
Sigma-Aldrich
Carbonato de calcio, BioReagent, suitable for insect cell culture, ≥99.0%
Sigma-Aldrich
Carbonato de calcio, ≥99.995% trace metals basis
Supelco
Carbonato de calcio, reference material for titrimetry, certified by BAM, ≥99.5%
Sigma-Aldrich
Carbonato de calcio, BioUltra, precipitated, ≥99.0% (KT)
Sigma-Aldrich
Carbonato de calcio, BioXtra, ≥99.0%
Supelco
Calcium Acetate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Carbonato de calcio, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99%
Sigma-Aldrich
Carbonato de calcio, tested according to Ph. Eur.